What changed in AbbVie Inc.'s latest annual report
In the year ended 31 Dec 2025, AbbVie Inc.'s revenue rose 8.6% to USD 61.16bn, from USD 56.33bn; net income fell 1.2% to USD 4.23bn, from USD 4.28bn; cash and cash equivalents fell 5.3% to USD 5.23bn, from USD 5.52bn.
Year ended 31 Dec 2025. Source: 10-K filed 20 Feb 2026, read it on SEC EDGAR.
USD 56.33bn to USD 61.16bn
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 56.33bn | 61.16bn | Up 8.6% |
| Net income | 4.28bn | 4.23bn | Down 1.2% |
| Total assets | 135.16bn | 133.96bn | Down 0.9% |
| Long-term debt | 66.84bn | 64.50bn | Down 3.5% |
| Cash and cash equivalents | 5.52bn | 5.23bn | Down 5.3% |
| Shareholders' equity | 3.33bn | -3.27bn | Not comparable |
Questions people ask
Did AbbVie Inc.'s revenue grow last year?
Revenue grew 8.6%, from USD 56.33bn to USD 61.16bn in the year ended 31 Dec 2025.
Is AbbVie Inc. profitable?
Yes. Net income was USD 4.23bn in the year ended 31 Dec 2025. The year before: USD 4.28bn.
How much cash and debt does AbbVie Inc. have?
At its latest year end (31 Dec 2025), AbbVie Inc. reported cash and cash equivalents of USD 5.23bn and long-term debt of USD 64.50bn.
Where do these numbers come from?
From AbbVie Inc.'s own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with AbbVie Inc.?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Pharmaceutical Preparations companies
- Eli Lilly And CompanyCash and cash equivalents up 122.4%
- Johnson & JohnsonNet income up 90.6%
- Merck & Co., Inc.Long-term debt up 35.7%
- Abbott LaboratoriesNet income down 51.3%
- Pfizer IncCash and cash equivalents up 9.5%
- Vertex Pharmaceuticals Inc / MaTotal liabilities up 13.9%
- Bristol-Myers Squibb CompanyShareholders' equity up 13.1%
- Regeneron Pharmaceuticals, Inc.Cash and cash equivalents up 25.3%